Urolithiasis in HIV-positive patients: prevalence and risk factors

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Today, the total number of people living with the human immunodeficiency virus (HIV) is 43.8 million. From the moment of infection to the terminal stage of the disease, the risk of stone formation progressively increases. A prevalence and role of individual risk factors for urolithiasis in patients with HIV are reviewed in the article. It is shown that in HIV-positive individuals, urolithiasis takes a leading position among renal diseases, with a prevalence ranging from 8 to 27%. The main risk factors for urolithiasis in HIV are: dietary factors, age, comorbid pathologies, use of protease inhibitors, changes in the ionic composition of urine, etc.

Толық мәтін

Рұқсат жабық

Авторлар туралы

I. Murkamilov

I.K. Akhunbaev Kyrgyz State Medical Academy, , Kyrgyzstan; Kyrgyz Russian Slavic University

Хат алмасуға жауапты Автор.
Email: murkamilov.i@mail.ru
ORCID iD: 0000-0001-8513-9279

Ph.D., MD, associate professor at the Department of Faculty Therapy of I.K. Akhunbaev Kyrgyz State Medical Academy, председатель правления Общества специалистов по хронической болезни почек of Kyrgyzstan, associate professor at the Department of Internal Disease No2 of GOU VPO KRSU named after B.N. Yeltsin

Қырғызстан, Bishkek; Bishkek

K. Aitbaev

Research Institute of Molecular Biology and Medicine

Email: kaitbaev@yahoo.com
ORCID iD: 0000-0003-4973-039X

Ph.D., MD, professor, Head of the Laboratory of Pathological Physiology of the Research Institute of Molecular Biology and Medicine of the Ministry of Health of the Kyrgyz Republic

Қырғызстан, Bishkek

V. Fomin

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: fomin_vic@mail.ru
ORCID iD: 0000-0002-2682-4417

corresponding member of RAS, Ph.D., MD, professor, Head of the Department of Faculty Internal Medicine No. 1, Vice-Rector for Innovation and Clinical Activities, FGAOU VO I.M. Sechenov First Moscow State Medical University (Sechenov University)

Ресей, Moscow

F. Yusupov

Osh State University

Email: furcat_y@mail.ru
ORCID iD: 0000-0003-0632-6653

Ph.D., MD, professor, Head of the Department of Neurology, Neurosurgery and Psychiatry of the Medical Faculty of Osh State University

Қырғызстан, Osh

Әдебиет тізімі

  1. Kirichenko A., Kireev D., Lapovok I., et al. Prevalence of Pretreatment HIV-1 Drug Resistance in Armenia in 2017-2018 and 2020-2021 following a WHO Survey. Viruses. 2022 Oct 22;14(11):2320. doi: 10.3390/v14112320.
  2. Gare J., Toto B., Pokeya P., et al. High prevalence of pre-treatment HIV drug resistance in Papua New Guinea: findings from the first nationally representative pre-treatment HIV drug resistance study. BMC Infect Dis. 2022 Mar 19;22(1):266. doi: 10.1186/s12879-022-07264-y.
  3. Xiong L., Loo N.N., Lu Z.Q., et al. Ureterolithiasis in Human Immunodeficiency Virus (HIV) Patients Treated with Single-Use Ureteroscope: A Case Report. Am J Case Rep. 2022 Dec 26;23:e938608. doi: 10.12659/AJCR.938608.
  4. Rassokhin V.V., Belyakov N.A., Rozental V.V., et al. Secondary and somatic diseases in HIV patients. HIV Infection and Immunosuppressive Disorders. 2014;6(1):7–18. doi: 10.22328/2077-9828-2014-6-1-7-18 Russian (Рассохин В.В., Беляков Н.А., Розенталь В.В., и др. Вторичные и соматические заболевания при ВИЧ-инфекции. ВИЧ-инфекция и иммуносупрессии. 2014;6(1):7–18. doi: 10.22328/2077-9828-2014-6-1-7-18)
  5. Chistova A.S. Urological diseases in HIV-positive patients. Materials of the All–Russian Scientific Forum with international participation «Youth Science Week 2020». Tyumen. 2020;255–256. Russian (Чистова А.С. Урологические заболевания у ВИЧ-положительных пациентов. Материалы Всероссийского научного форума с международным участием «Неделя молодежной науки-2020». Тюмень. 2020;255–256).
  6. Zabirov K.I., Maksimov V.A., Yarovoy S.K., et al. Urological diseases in HIV-positive patients. Infectious diseases.2009;7:4:54–56. Russian (Забиров К.И., Максимов В.А., Яровой С.К., и др. Урологические заболевания у ВИЧ-инфицированных больных. Инфекционные болезни.2009;7:4:54–56).
  7. Grigorian O.M., Alekseeva G.N., Cherlanova T.S., et al. The analysis of urological morbidity in HIV-infected patients of the Vladivostok City District. Zdorov’e Naseleniya i Sreda Obitaniya. 2020;8(329):64–68. doi: 10.35627/2219-5238/2020-329-8-64-68 Russian (Григорян О.М., Алексеева Г.Н., Черланова Т.С., и др. Анализ урологической заболеваемости ВИЧ-инфицированных пациентов Владивостокского городского округа.Здоровье населения и среда обитания. 2020;8(329):64–68. doi: 10.35627/2219-5238/2020- 329-8-64-68)
  8. Raheem O.A., Mirheydar H.S., Palazzi K., et al. Prevalence of nephrolithiasis in human immunodeficiency virus infected patients on the highly active antiretroviral therapy. J Endourol. 2012 Aug;26(8):1095–1098. doi: 10.1089/end.2011.0639.
  9. Yang C.J., Wang H.Y., Chou T.C., Chang C.J. Prevalence and related drug cost of comorbidities in HIV-infected patients receiving highly active antiretroviral therapy in Taiwan: A cross-sectional study. J Microbiol Immunol Infect. 2019 Oct;52(5):720–727. doi: 10.1016/j.jmii.2019.05.011.
  10. Lin K.Y., Liao S.H., Liu W.C., et al. Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy. PLoS One. 2015 Sep 11;10(9):e0137660. doi: 10.1371/journal.pone.0137660.
  11. Romantsov M.G., Ershov F.I., Kovalenko A.L., et al. The duration of an HIV infection course and its influencing factors. Terapevticheskii Arkhiv.2014;86(11):2010923.Russian (Романцов М.Г., Ершов Ф.И., Коваленко А.Л., и др. Продолжительность течения ВИЧ-инфекции и влияющие на нее факторы. Терапевтический архив. 2014;86(11):20–3).
  12. Mwanjala M.N., Urio L.J., Mtebe M.V. Prevalence and predictors of renal dysfunction among people living with HIV on antiretroviral therapy in the Southern Highland of Tanzania: a hospital-based cross-sectional study. Pan Afr Med J. 2022 Feb 17;41:137. doi: 10.11604/pamj.2022.41.137.27025.
  13. Nadler R.B., Rubenstein J.N., Eggener S.E., et al. The etiology of urolithiasis in HIV infected patients. The Journal of urology.2003;169:2:475-477. doi: 10.1016/S0022-5347(05)63936-5.
  14. Izzedine H., Lescure F.X., Bonnet F. HIV medication based urolithiasis. Clin Kidney J. 2014; 7(2):121–126. doi: 10.1093/ckj/sfu008.
  15. Daudon M., Frochot V., Bazin D., Jungers P. Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment. Drugs.2018 Feb;78(2):163–201. doi: 10.1007/s40265-017-0853-7.
  16. Gagnon R.F., Tecimer S.N., Watters A.K., Tsoukas C.M. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis.2000;36:507–515.
  17. Menghua W., Xin Z., Bohan F., et al. The analysis of Upper tract Urinary Stone Composition in HIV-positive Patients: a single center experience.2020. doi: 10.21203/rs.3.rs-29836/v1.
  18. Golovanov S.A., Sivkov A.V., Polikarpova A.M., et al. Metabolic risk factors and formation of urinary stones. Study III: Effect of urine pH. Experimental and clinical urology. 2018;1:84–89. doi: 10.29188/2222-8543-2018-9-1-84-90 Russian (Голованов С.А., Сивков А.В., Поликарпова А.М., и др. Метаболические факторы риска и формирование мочевых камней. Исследование III: Влияние pH мочи. Экспериментальная и клиническая урология.2018;1:84–89. doi: 10.29188/2222-8543-2018-9-1-84-90)
  19. Tiselius HG. Risk formulas in calcium oxalate urolithiasis. World J Urol.1997;15(3):176–185. doi: 10.1007/BF02201855.
  20. Daudon M., Frochot V. Crystalluria. ClinChem Lab Med.2015;53 (Suppl 2):s1479–1487. doi: 10.1515/cclm-2015-0860.
  21. Grases F., Villacampa A.I., Costa-Bauzá A., Söhnel O. Uric acid calculi: types, etiology and mechanisms of formation. Clin Chim Acta. 2000 Dec;302(1–2):89–104. doi: 10.1016/s0009-8981(00)00359-4.
  22. Nishijima T., Hamada Y., Watanabe K., et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS One. 2013 Oct 10;8(10):e77268. doi: 10.1371/journal.pone.0077268.
  23. Ryom L., Dilling Lundgren J., Reiss P., et al. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis.2019 Oct 8;220(10):1629–1634. doi: 10.1093/infdis/jiz369.
  24. Pulin A.A., Kustova T.Iu., Fomin V.V., et al. Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection. Terapevticheskii Arkhiv.2014;86(11):29–33. Russian (Пулин А.А., Кустова Т.Ю., Фомин В.В., и др. Результаты сравнительного исследования эффективности применения дарунавира и атазанавира один раз в день у больных ВИЧ-инфекцией, ранее не получавших лечения. Терапевтический архив. 2014;86(11):29–33).
  25. Menéndez-Arias L., Delgado R. Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2022 Jan;43(1):16–29. doi: 10.1016/j.tips.2021.10.004.
  26. Nishijima T., Tsuchiya K., Tanaka N., et al. Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3’ untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. J Antimicrob Chemother. 2014 Dec;69(12):3320–3328. doi: 10.1093/jac/dku304.
  27. Sury K., Perazella M.A. The changing face of human immunodeficiency virus-mediated kidney disease. Advances in Chronic Kidney Disease.2019;26:3:185–197. doi: 10.1053/j.ackd.2018.12.001.
  28. Wirth G.J., Teuscher J., Graf J.D., Iselin C.E. Efavirenz-induced urolithiasis. Urol Res.2006;34:288–289. Doi: 0.1007/s00240-006-0052-6.
  29. Khalil C., Mohanty M.J., Kaatz G., Abu-Hamdan D.Efavirenz-associated urinary Matrix stone-A rare presentation. Am J Med Sci.2016;351:213–214. doi: 10.1016/j.amjms.2015.11.020.
  30. McLaughlin M.M., Guerrero A.J., Merker A. Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV. Drugs Context. 2018 Mar 21;7:212519. doi: 10.7573/dic.212519.
  31. Gozhenko A.I., Gorobets O.P., Goydyk V.S., et al. The urinary syndrome in hiv-infected patients in the stage of aids. Nephrology (Saint-Petersburg). 2008;12(4):54–58. doi: 10.24884/1561-6274-2008-12-4-54-58 Russian (Гоженко А.И., Горобець О.П., Гойдик В.С., и др. Мочевой синдром у ВИЧ-инфицированных больных в стадии спида. Нефрология. 2008;12(4):54–58. doi: 10.24884/1561-6274-2008-12-4-54-58).
  32. Dauchy F.A., Lawson-Ayayi S., de La Faille R., et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011 Aug;80(3):302–309. doi: 10.1038/ki.2011.124.
  33. Cicconi P., Bongiovanni M., Melzi S., et al. Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir. Int J Antimicrob Agents. 2004 Sep;24(3):284–285. doi: 10.1016/j.ijantimicag.2004.04.005.
  34. Gadzhiev N.K., Gelig V.A., Kutina A.V., et al. Urinary pH: its regulation and relevance in urolithiasis metaphylaxis. Urology Herald. 2022;10(4):120–140. doi: 10.21886/2308-6424-2022-10-4-120-140 Russian (Гаджиев Н.К., Гелиг В.А., Кутина А.В., и др. Кислотно-основное состояние (pH) мочи: механизм регуляции и его роль в метафилактике мочекаменной болезни. Вестник урологии. 2022;10(4):120–140. doi: 10.21886/2308-6424-2022-10-4-120-140).
  35. Daudon M., Frochot V. Crystalluria. Clin Chem Lab Med. 2015;53(Suppl 2):s1479–1487. doi: 10.1515/cclm-2015-0860.
  36. Hesse A., Schneider H.J., Berg W., Hienzsch E. Uric acid dihydrate as urinary calculus component. Invest Urol. 1975 Mar;12(5):40514409.
  37. Morrison V.V., Chesnokova N.P., Bizenkova M.N. Acid-base state. regulation of acid-base homeostasis (lecture 1). International Journal of Applied and Fundamental Research.2015;3-2:270-273 Russian (Моррисон В.В., Чеснокова Н.П., Бизенкова М.Н. Кислотно-основное состояние. регуляция кислотно-основного гомеостаза (лекция 1). Международный журнал прикладных и фундаментальных исследований.2015;3-2:270-273).
  38. Zeng G., Zhao Z., Mazzon G., et al. European Association of Urology Section of Urolithiasis and International Alliance of Urolithiasis Joint Consensus on Retrograde Intrarenal Surgery for the Management of Renal Stones. Eur Urol Focus. 2022 Sep;8(5):1461–1468. doi: 10.1016/j.euf.2021.10.011.
  39. Ilyas R., Chow K., Young J.G. What is the best method to evaluate urine pH? A trial of three urinary pH measurement methods in a stone clinic. J Endourol. 2015 Jan;29(1):70–74. doi: 10.1089/end.2014.0317.
  40. Johnston C.D., Siegler E.L., Rice M.C., et al. Urine Cell-Free Mitochondrial DNA as a Marker of Weight Loss and Body Composition in Older Adults With HIV. J Acquir Immune Defic Syndr. 2021 Nov 1;88(3):229–233. doi: 10.1097/QAI.0000000000002766.
  41. Brito R.M., Nguyen D.T., Johnson J.R., et al. Chronic kidney disease in patients infected with human immunodeficiency virus (HIV) in an urban cohort. PLoS One. 2019 Apr 17;14(4):e0215575. doi: 10.1371/journal.pone.0215575.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2023

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>